Oxaliplatine Medac (Oxaliplatin)

Oxaliplatin is used in colorectal cancer treatment protocols that target the DNA replication pathway.

• Colorectal cancer: Enhances tumor response when combined with fluoropyrimidines and leucovorin.
• Adjuvant therapy post‑surgery: Reduces risk of cancer recurrence after curative resection.
• Metastatic colorectal cancer: Contributes to disease control in combination regimens.

• Oxaliplatin forms reactive platinum‑DNA adducts that disrupt DNA replication and transcription, leading to cell‑cycle arrest and apoptosis in rapidly dividing tumor cells. The drug’s diaminocyclohexane carrier ligand enhances intracellular accumulation and cytotoxic potency compared with earlier platinum compounds.

Oxaliplatin may cause a range of adverse reactions, from mild to severe, requiring monitoring throughout therapy.

Common Side Effects

• Nausea and vomiting: Frequently observed during infusion.
• Peripheral neuropathy: Tingling or numbness, often dose‑related.
• Diarrhea: May range from mild to moderate severity.
• Fatigue: Generalized tiredness reported by many patients.
• Myelosuppression: Decreased blood cell counts, increasing infection risk.
• Elevated liver enzymes: Transient changes in hepatic function tests.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: Including anaphylaxis.
• Persistent neuropathy: May become irreversible after cumulative dosing.
• Acute hemolytic anemia: Rare but potentially life‑threatening.
• Cardiac arrhythmias: Uncommon electrocardiographic changes.
• Severe neutropenia with fever: High infection risk requiring urgent care.

Oxaliplatin therapy requires careful assessment of patient health status and ongoing monitoring to mitigate risks.

• Renal function assessment: Adjust dosing in patients with impaired kidney function.
• Baseline neuropathy evaluation: Monitor for worsening peripheral sensations.
• Hepatic function monitoring: Check liver enzymes before each cycle.
• Pregnancy and lactation warning: Avoid use unless benefits outweigh risks.
• Concomitant ototoxic drugs: Use with caution to reduce hearing loss risk.
• Store at below 25°C: Keep in original packaging, protect from light and moisture.

Oxaliplatin may interact with several drug classes, influencing efficacy or toxicity.

Major Interactions (Avoid)

• Nephrotoxic agents: Concurrent use may exacerbate renal impairment.
• Highly emetogenic chemotherapy: May increase severity of nausea and vomiting.

Moderate Interactions (Monitor Closely)

• Anticoagulants: May enhance bleeding risk during thrombocytopenia.
• CYP450 inducers: Potentially reduce plasma concentrations of co‑administered drugs.
• Radiotherapy: May potentiate local tissue toxicity when given concurrently.